Multiple Myeloma Clinical Trial
Official title:
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Verified date | June 2024 |
Source | Janssen Research & Development, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Status | Active, not recruiting |
Enrollment | 395 |
Est. completion date | October 31, 2028 |
Est. primary completion date | August 29, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of multiple myeloma as documented per International Myeloma Working Group (IMWG) criteria Monoclonal plasma cells in the bone marrow greater than or equal to (>=)10 percentage (%) or presence of a biopsy proven plasmacytoma and documented multiple myeloma satisfying at least one of the calcium, renal, anemia, bone (CRAB) criteria or biomarkers of malignancy criteria. CRAB criteria: Hypercalcemia: serum calcium greater than (>) 0.25 millimoles per liter (mmol/L) (>1 milligram per deciliter [mg/dL]) higher than upper limit of normal (ULN) or >2.75 mmol/L (>11 mg/dL); Renal insufficiency: creatinine clearance less than (<) 40 milliliter per minute (mL/min) or serum creatinine >177 micro millimoles per liter (umol/L) (>2 mg/dL); Anemia: hemoglobin >2 g/dL below the lower limit of normal or hemoglobin <10 g/dL; Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)-CT. Biomarkers of Malignancy: Clonal bone marrow plasma cell percentage >=60%; Involved: uninvolved serum free light chain (FLC) ratio >=100; >1 focal lesion on magnetic resonance imaging (MRI) studies - Must have measurable disease, as assessed by central laboratory - Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 - A woman of childbearing potential must have 2 negative serum or urine pregnancy tests at Screening, first within 10 to 14 days prior to dosing and the second within 24 hours prior to dosing - A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 3 months after receiving the last dose of any component of the treatment regimen Exclusion Criteria: - Frailty index of >=2 according to Myeloma Geriatric Assessment score - Prior therapy for multiple myeloma other than a short course of corticosteroids (not to exceed 40 mg of dexamethasone, or equivalent per day, total of 160 mg dexamethasone or equivalent) - Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years of date of randomization (exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years) - Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5 - Focal radiation therapy within 14 days of randomization with the exception of palliative radiotherapy for symptomatic pain management. Radiotherapy within 14 days prior to randomization on measurable extramedullary plasmacytoma is not permitted even in the setting of palliation for symptomatic management |
Country | Name | City | State |
---|---|---|---|
Brazil | Universidade Estadual De Campinas | Campinas | |
Brazil | Liga Norte Riograndense Contra O Cancer | Natal | |
Brazil | Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS | Porto Alegre | |
Brazil | Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI) | Rio de Janeiro | |
Brazil | Ministerio da Saude - Instituto Nacional do Cancer | Rio de Janeiro | |
Brazil | Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia | Sao Paulo | |
Brazil | Instituto de Ensino e Pesquisa São Lucas | Sao Paulo | |
Brazil | Real e Benemerita Associacao Portuguesa de Beneficencia | Sao Paulo | |
Brazil | Clinica Sao Germano | São Paulo | |
Brazil | Hospital Santa Cruz | São Paulo | |
Canada | Brampton Civic Hospital | Brampton | Ontario |
Canada | Tom Baker Cancer Centre | Calgary | Alberta |
Canada | Cross Cancer Institute | Edmonton | Alberta |
Canada | QEII Health Sciences Centre | Halifax | Nova Scotia |
Canada | Victoria Hospital | London | Ontario |
Canada | McGill University Health Centre | Montreal | Quebec |
Canada | Lakeridge Health Oshawa | Oshawa | Ontario |
Canada | CHU de Quebec L Hotel Dieu de Quebec | Quebec | |
Canada | The Gordon & Leslie Diamond Health Care Center | Vancouver | British Columbia |
Czechia | Fakultni nemocnice Brno | Brno | |
Czechia | Fakultni nemocnice Hradec Kralove | Hradec Kralove | |
Czechia | Fakultni nemocnice Ostrava | Ostrava | |
Czechia | Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni | Plzen | |
Czechia | Vseobecna fakultni nemocnice v Praze | Praha 2 | |
France | CHU Henri Mondor | Creteil N/a | |
France | Centre Hospitalier Départmental La Roche sur Yon | La Roche sur Yon Cedex 9 | |
France | Hopital Claude Huriez | Lille | |
France | Institut Paoli Calmettes | Marseille Cedex 9 | |
France | CHU de Montpellier, Hopital Saint-Eloi | Montpellier | |
France | CHU de Bordeaux - Hospital Haut-Leveque | Pessac cedex | |
France | Strasbourg Oncologie Libérale | Strasbourg | |
France | Institut Universitaire du cancer de Toulouse-Oncopole | Toulouse cedex 9 | |
Germany | phase 3 - Hämatoonkologischer Studienkreis am Klinikum Aschaffenburg | Aschaffenburg | |
Germany | Universitatsklinikum Freiburg | Freiburg | |
Germany | St. Josef-Krankenhaus Hamm-Bockum-Hövel | Hamm | |
Germany | Institut für Versorgungsforschung | Koblenz | |
Germany | Universitatsmedizin Leipzig | Leipzig | |
Germany | Klinikum Großhadern der Ludwig-Maximilians-Universität | München | |
Germany | Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, | Tuebingen | |
Israel | Barzilai Medical Center | Ashkelon | |
Israel | Hillel Yaffe Medical Center | Hadera | |
Israel | Carmel Medical Center | Haifa | |
Israel | Rambam Med.Center - Hematology Institute | Haifa | |
Israel | Meir Hospital | Kfar Saba | |
Israel | Rabin Medical Center | Petah-Tiqva | |
Israel | Sheba Medical Center | Ramat Gan | |
Israel | Sourasky (Ichilov) Medical Center | Tel Aviv | |
Japan | Fukuoka University Hospital | Fukuoka | |
Japan | Ogaki Municipal Hospital | Gifu | |
Japan | Kanazawa University Hospital | Kanazawa | |
Japan | Kobe City Medical Center General Hospital | Kobe City | |
Japan | National Hospital Organization Kumamoto Medical Center | Kumamoto-shi | |
Japan | University Hospital Kyoto Perfectural University of Medicine | Kyoto | |
Japan | National Hospital Organization Matsumoto Medical Center | Matsumoto | |
Japan | Matsuyama Red Cross Hospital | Matsuyama | |
Japan | Nagoya City University Hospital | Nagoya | |
Japan | National Hospital Organization Okayama Medical Center | Okayama | |
Japan | Japanese Red Cross Osaka Hospital | Osaka | |
Japan | National Hospital Organization Shibukawa Medical Center | Shibukawa | |
Japan | Japanese Red Cross Medical Center | Shibuya | |
Netherlands | VU Medisch Centrum | Amsterdam | |
Netherlands | Albert Schweitzer ziekenhuis-lokatie Dordwijk | Dordrecht | |
Netherlands | Erasmus MC | Rotterdam | |
Poland | Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza | Brzozow | |
Poland | Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich | Chorzów | |
Poland | Uniwersyteckie Centrum Kliniczne | Gdansk | |
Poland | Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach | Kielce | |
Poland | NSSU Szpital Uniwersytecki w Krakowie | Krakow | |
Poland | Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli | Lublin | |
Poland | Uniwersytecki Szpital Kliniczny w Poznaniu | Poznan | |
Poland | Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka | Slupsk | |
Poland | Instytut Hematologii i Transfuzjologii | Warszawa | |
Poland | Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy | Warszawa | |
Spain | Hosp. Univ. Fundacion Alcorcon | Alcorcon | |
Spain | Hosp. Del Mar | Barcelona | |
Spain | Hosp. Univ. de Guadalajara | Guadalajara | |
Spain | Hosp. Univ. Pta. de Hierro Majadahonda | Majadahonda | |
Spain | Hosp. Quiron Madrid Pozuelo | Pozuelo De Alarcon, Madrid | |
Spain | Hosp. Mutua Terrassa | Terrassa | |
Turkey | Ankara University School of Medicine Cebeci Hospital | Ankara | |
Turkey | Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital | Ankara | |
Turkey | Gulhane Egitim ve Arastirma Hastanesi | Ankara | |
Turkey | Hacettepe University Medical Faculty | Ankara | |
Turkey | Istanbul University Istanbul Medical Faculty | Istanbul | |
Turkey | Dokuz Eylul University Medical Faculty | Izmir | |
Turkey | Ondokuz Mayis Universitesi Tip Fakultesi | Samsun | |
United Kingdom | Monklands District General Hospital | Airdrie | |
United Kingdom | Blackpool Victoria Hospital | Blackpool | |
United Kingdom | University Hospital Wales | Cardiff | |
United Kingdom | Colchester Hospital University NHS | Colchester | |
United Kingdom | Leicester Royal Infirmary - Haematology | Leicester | |
United Kingdom | Altnagelvin Hospital | Londonderry | |
United Kingdom | The Royal Oldham Hospital | Oldham | |
United Kingdom | Derriford Hospital | Plymouth | |
United Kingdom | New Cross Hospital | Wolverhampton | |
United States | Boston University Medical Center | Boston | Massachusetts |
United States | Tufts Medical Center | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Innovative Clinical Research Inc | Cerritos | California |
United States | Levine Cancer Institute | Charlotte | North Carolina |
United States | University of Virginia | Charlottesville | Virginia |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Good Samaritan Hospital Corvallis | Corvallis | Oregon |
United States | San Juan Oncology Associates | Farmington | New Mexico |
United States | Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne | Indiana |
United States | Cancer And Hematology Centers of Western Michigan PC | Grand Rapids | Michigan |
United States | University of Texas, MD Anderson Cancer Center | Houston | Texas |
United States | Baptist MD Anderson | Jacksonville | Florida |
United States | Saint Luke's Hospital - Saint Luke's Cancer Specialists | Kansas City | Missouri |
United States | Norton Healthcare | Louisville | Kentucky |
United States | NYU Winthrop | Mineola | New York |
United States | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center | Pittsburgh | Pennsylvania |
United States | Gibbs Cancer Center | Spartanburg | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Janssen Research & Development, LLC |
United States, Brazil, Canada, Czechia, France, Germany, Israel, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Negative Minimal Residual Disease (MRD) Status | Percentage of participants who achieve MRD negative status by evaluation of bone marrow aspirates using next generation sequencing (NGS) at 10^-5 threshold will be assessed. | After randomization and prior to progressive disease (PD) or the start of subsequent anti-myeloma therapy approximately 2.5 years | |
Secondary | Progression-Free Survival (PFS) | PFS is defined as the duration from date of randomization to either PD or death, whichever comes first. International Myeloma Working Group (IMWG) criteria for PD: Increase of 25 percentage (%) from lowest response value in any one of following: Serum M-component (absolute increase must be >= 0.5 gram per deciliter [g/dL],) Urine M-component (absolute increase must be >=200 mg/24 hours), participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels (absolute increase must be >10 milligrams per deciliter [mg/dL]), participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC% (absolute percentage must be >=10%), definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or tissue plasmacytomas and development of hypercalcemia (serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. | From randomization to either disease progression or death whichever occurs first (approximately 6 years, or 9 years if the adaptive approach is decided at the interim) | |
Secondary | MRD Negative Rate | Percentage of participants who have achieved MRD negative status will be assessed and landmark timepoints (12, 18 and 24 months). MRD negativity will be evaluated as a potential surrogate for PFS and overall survival (OS) in multiple myeloma treatment. | 12,18 and 24 Months | |
Secondary | Durable MRD Negative Rate | Durable MRD negativity rate is defined as the number of participants who have achieved MRD negative status (at 10^-5) at 2 bone marrow aspirates examinations that are a minimum of 1 year apart, without any examination showing MRD positive status in between. | Throughout the study (approximately 6 year) | |
Secondary | Overall Response Rate (ORR) | ORR is defined as the percentage of participants who achieve partial response (PR) or better responses prior to subsequent anti-myeloma therapy in accordance with IMWG criteria, during or after the study treatment. IMWG criteria for PR: greater than or equal to (>=) 50 reduction of serum M-protein and reduction in 24-hour urinary M-protein by >=90 % or to less than (<) 200 mg/24 hours, If the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, >=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was >=30%. In addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required. | Up to the end of the study (approximately 6 years) | |
Secondary | Very Good Partial Response (VGPR) or Better Rate | VGPR or better rate is defined as the percentage of participants achieving VGPR and complete response (CR) (including stringent complete response [sCR]) prior to subsequent anti-myeloma therapy in accordance with the IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or greater than or equal to (>=) 90 % reduction in serum M-protein plus urine M-protein <100 milligram per 24 hours (mg/24 hours); CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and <5% PCs in bone marrow. sCR: CR plus normal FLC ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescence or 2- to 4 color flow cytometry. | Approximately 6 years | |
Secondary | Complete Response (CR) or Better Rate | CR or better rate is defined as the percentage of participants achieving CR or sCR prior to subsequent anti-myeloma therapy in accordance with the IMWG criteria during or after the study treatment. | Approximately 6 years | |
Secondary | PFS on the Next Line of Therapy | The PFS on the next line of therapy is defined as the time from randomization to progression on the next line of treatment or death, whichever comes first. Disease progression will be based on investigator judgment. | Time from randomization to progression on the next line of treatment or death, whichever comes first (up to approximately 6 years, or 9 years if the adaptive approach is decided at the interim) | |
Secondary | Overall Survival (OS) | OS is defined as the time from the date of randomization to the date of the participant's death due to any cause. | From randomization until the participant's death from any cause (up to approximately 6 years, or 9 years if the adaptive approach is decided at the interim) | |
Secondary | Time to Response | Time to response is defined as the time between the randomization and the first efficacy evaluation at which the participant meets all criteria for PR or better. | From randomization until PR or better until approximately 6 years | |
Secondary | Duration of Response (DOR) | DOR is calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD, as defined in the IMWG evaluation before the start of any subsequent anti-myeloma therapy. | From initial documentation of response to the date of PD until approximately 6 years | |
Secondary | Maximum Observed Serum Concentration (Cmax) of Daratumumab | The Cmax is the maximum observed serum concentration of daratumumab. | Predose Cycle 1, Day 1 (C1D1), C3D1, C9D1, C12D1, and post dose C1D4, C3D4, Post-treatment Week 8 (Cycle 1 to 8 is of 21 days; Cycle 9 and onwards are of 28 days) | |
Secondary | Minimum Observed Serum Concentration (Cmin) of Daratumumab | The Cmin is the minimum observed serum concentration of daratumumab. | Predose, C1D1 (each cycle of 28 days), C3D1, C9D1, C12D1, and post dose C1D4, C3D4, Post-treatment Week 8 (Cycle 1 to 8 is of 21 days; Cycle 9 and onwards are of 28 days) | |
Secondary | Number of Participants with Anit-daratumumab Antibodies | Number of participants with anti-daratumumab antibodies will be assessed. | Predose, C1D1 (each cycle of 28 days), C9D1, C12D1, Post-treatment Week 8 (Cycle 1 to 8 is of 21 days; Cycle 9 and onwards are of 28 days) | |
Secondary | Number of Participants with Anit-rHuPH20 Antibodies | Number of participants with anti-recombinant human hyaluronidase (rHuPH20) antibodies will be assessed. | Predose, C1D1 (each cycle of 28 days), C9D1, C12D1, Post-treatment Week 8 (Cycle 1 to 8 is of 21 days; Cycle 9 and onwards are of 28 days) | |
Secondary | Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC QLQ-C30) | The EORTC- QLQ-Core-30 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms. | Baseline, up to 6 years (end of study) | |
Secondary | Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Multiple Myeloma 20-item (EORTC QLQ-MY20) | The EORTC QLQ-MY20 is a validated, self -administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). | Baseline, up to 6 years (end of study) | |
Secondary | Change from Baseline in HRQoL as Assessed by EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L) | The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores for the 5 separate questions are categorical and cannot be analyzed as cardinal numbers. | Baseline, up to 6 years (end of study) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |